Subtype
Breast Carcinoma by Gene Expression Profile
CI-CAN-00004666Explore in graph →
537 active trials6 approved drugs101 evidence items
- NCIt
- C53553
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004666Explore in graph →
Clinical trials
1,299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (217)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02734290 | Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 29 | Providence Health & ServicesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06134375 | A Study of Tetrathiomolybdate (TM) Plus Capecitabine | recruiting | Phase 1 / Phase 2 | 204 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05081492 |
| CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer |
| active not recruiting |
| Phase 1 |
| 9 |
| City of Hope Medical CenterOTHER |
| 1 |
| Apr 17, 2026 |
| clinicaltrials |
| NCT02802423 | Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. | not yet recruiting | Phase 1 / Phase 2 | 44 | BioLite, Inc.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT06547840 | A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha | recruiting | Phase 1 | 45 | Epsilogen LtdINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07510802 | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors(BetaBart) | recruiting | Phase 1 / Phase 2 | 61 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07486089 | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)(DUAL-NK-BC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06908928 | A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs | recruiting | Phase 1 | 52 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07454668 | Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases | not yet recruiting | Phase 1 | 20 | Baptist Health South FloridaOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07190469 | PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer | recruiting | Phase 1 | 80 | ProteinQure Inc.INDUSTRY | 2 | Feb 23, 2026 | clinicaltrials |
| NCT07423117 | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy | not yet recruiting | Phase 1 | 102 | IntoCell, IncINDUSTRY | 0 | Feb 20, 2026 | clinicaltrials |
| NCT07208149 | A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) | recruiting | Phase 1 / Phase 2 | 42 | Shenzhen Majory Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07281976 | A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 220 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05383196 | Onvansertib + Paclitaxel In TNBC | active not recruiting | Phase 1 / Phase 2 | 50 | Antonio Giordano, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05504707 | DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer(DecipHER) | recruiting | Phase 1 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06926920 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 100 | Gilead SciencesINDUSTRY | 3 | Jan 30, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06324240 | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer | recruiting | Phase 1 | 18 | Emory UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT03368729 | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | University of Alabama at BirminghamOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03891953 | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | active not recruiting | Phase 1 | 98 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 21, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT03090165 | Ribociclib and Bicalutamide in AR+ TNBC | active not recruiting | Phase 1 / Phase 2 | 37 | Kari WisinskiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT06238921 | Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases | recruiting | Phase 1 / Phase 2 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT07178171 | A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC | recruiting | Phase 1 | 30 | Xijing HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06328738 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | active not recruiting | Phase 1 | 275 | Enliven TherapeuticsINDUSTRY | 7 | Nov 19, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT04561362 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 329 | BicycleTx LimitedINDUSTRY | 6 | Nov 14, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03589339 | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | active not recruiting | Phase 1 | 145 | NanobiotixINDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT02393794 | Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 1 / Phase 2 | 51 | Priyanka SharmaOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT05806385 | Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers(LOGIC) | not yet recruiting | Phase 1 / Phase 2 | 36 | Texas Tech University Health Sciences CenterOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07161791 | Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 12 | Harbin Medical UniversityOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07139470 | Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 59 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT06036121 | A Study of ADRX-0706 in Select Advanced Solid Tumors | active not recruiting | Phase 1 | 144 | Adcentrx TherapeuticsINDUSTRY | 2 | Aug 17, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Apr 24, 2026source: clinicaltrials